SGAM
IONS icon

Smith Group Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Smith Group Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-176,510
Closed -$8.88M – 448
2017
Q4 		$8.88M Sell
176,510
-6,790
-4% -$372K 0.28% 82
2017
Q3 		$9.29M Sell
183,300
-40,680
-18% -$2.13M 0.31% 76
2017
Q2 		$11.4M Buy
+223,980
New +$10.4M 0.35% 73

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Smith Group Asset Management's IONS Position: Q1 2018 in Review

Smith Group Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2018, closing a stake of 176,510 shares — an estimated $8.88M sold.

Smith Group Asset Management first reported a position in IONS in Q2 2017 and held it in 3 quarters. The position peaked at $11.4M in Q2 2017. 325 funds tracked by Wall St. Rank hold IONS as of Q1 2018.

  • Smith Group Asset Management reported no remaining Ionis Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Smith Group Asset Management sold 176,510 Ionis Pharmaceuticals shares in Q1 2018, an estimated $8.88M.
  • Smith Group Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Smith Group Asset Management's Ionis Pharmaceuticals position peaked at $11.4M in Q2 2017.
  • 325 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2018.

Based on Smith Group Asset Management's 13F filing for Q1 2018, filed 8 May 2018.